ASH 2023 | Screening for CHIP to detect potential TMNs in cancer treatment
Rena Buckstein, MD, FRCPC, Odette Cancer Research Program, Sunnybrook Research Institute, Toronto, Canada, discusses screening for clonal hematopoiesis of indeterminate potential (CHIP), a risk factor for therapy-related myeloid neoplasms (TMNs) in cancer treatment. While Dr Buckstein does not currently recommend CHIP screening due to insufficient data on its negative effects, she suggests that additional surveillance may be beneficial. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Abbvie: Honoraria; Taiho: Honoraria, Research Funding; BMS: Honoraria, Research Funding.
